Using mathematical models to improve immune therapy for bladder cancer
Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
This study is exploring a new way to treat bladder cancer by using your own immune cells to fight the disease, and it aims to make the treatment more effective and easier on your body by giving smaller doses directly into the bladder.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-11053601 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating bladder cancer by utilizing adoptive cell therapy (ACT), where a patient's own immune cells are expanded and activated outside the body before being reinfused. The study aims to optimize this therapy by using mathematical modeling to design and validate treatment protocols that can be administered directly into the bladder, allowing for more frequent and smaller doses of therapy. By integrating pre-clinical mouse models and experimental data, the research seeks to maximize the effectiveness of the treatment while minimizing side effects for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with bladder cancer who are seeking innovative treatment options.
Not a fit: Patients with bladder cancer who are not eligible for immunotherapy or those with advanced metastatic disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatment options for patients with bladder cancer.
How similar studies have performed: Previous research has shown promise in using adoptive cell therapy for various cancers, indicating potential success for this novel approach in bladder cancer.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Rejniak, Katarzyna Anna — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Rejniak, Katarzyna Anna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.